|
Tillman Gerngross is an American scientist. He is a Professor of Bioengineering at the Thayer School of Engineering at Dartmouth College, and an Adjunct Professor in the departments of Biology and Chemistry at Dartmouth. Gerngross has been an active inventor and to date his work has resulted in the founding of two companies (GlycoFi, Inc. and (Adimab LLC. )) and over a dozen U.S. and international patents.()() ==Academic background== Gerngross received a M.S. (Dipl. Ing.) in Chemical Engineering (1989) and later a (Ph.D. ) in Molecular Biology from the Technical University of Vienna, Austria. Following his studies in Austria he became a visiting scientist at the Massachusetts Institute of Technology in the laboratory of Arnold Demain (1989–91) and later joined the laboratory of Anthony Sinskey and JoAnne Stubbe at MIT as a Postdoctoral Associate from 1991 to 1993. From 1993 till 1998 he headed the fermentation and process development group at Metabolix Inc., a small startup company in Cambridge, Massachusetts. In 1998 he left industry to join the faculty at Dartmouth where he focused his research on protein engineering, glycoprotein engineering in yeast, and life cycle analysis of competing manufacturing technologies. In addition to this work, Gerngross’ lab also developed a novel protein expression system based on the industrial fermentation organisms ''Ralstonia eutropha'', formerly ''Alcaligenes eutrophus''. With certain model proteins, this expression system has shown to outperform ''E. coli'', the well proven workhorse of prokaryotic protein expression. The work on ''Ralstonia eutropha'' was later expanded in collaboration with Prof. Wood at Princeton University to combine recombinant expression of proteins with the ability to purify them in vivo. In the late 1990s Gerngross became one of the first vocal critics of biobased processes. By using life cycle assessment tools he demonstrated the shortcomings of bioplastics and similar biomass based technologies intended as a substitute for the petrochemical processes used today. His main findings showed that changing from petrochemical to biomass-based processes often worsens their environmental impact and increases the emissions of carbon dioxide when compared to conventional processes based on fossil fuel stocks. With the recent mandate to increase biofuel content in the United States this area of research has become increasingly important, but to date has failed to guide public policy in the United States. Arguably, Gerngross' most important biotechnological contribution consisted of humanizing the glycosylation machinery in yeast to produce human therapeutic proteins, including antibodies, with fully human carbohydrate structures. Much of this work was conducted at Glycofi, Inc., a Lebanon, New Hampshire biotechnology startup company that was acquired in 2006 by Merck in a record-setting $400 million transaction. His work has been frequently cited in the popular press including ''The Times'' (London), CNN, ''Scientific American'', BBC, ''The Guardian'', ''The Economist'', ''New Scientist'',〔http://www.newscientist.com/article.ns?id=dn4106〕 ''Nature Biotechnology'' and the ''Los Angeles Times''. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Tillman Gerngross」の詳細全文を読む スポンサード リンク
|